It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he would withdraw from ...

Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...